Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price target lowered by HC Wainwright from $12.00 to $10.00 in a report published on Friday, Benzinga reports. The firm currently has a buy rating on the stock. Other analysts have also issued reports about the company. Guggenheim lowered Allogene Therapeutics from a buy rating to a […]